CLGN vs. RBOT, COCH, MLSS, LFWD, NTRB, INGN, ELUT, YS, CARM, and VHAQ
Should you be buying CollPlant Biotechnologies stock or one of its competitors? The main competitors of CollPlant Biotechnologies include Vicarious Surgical (RBOT), Envoy Medical (COCH), Milestone Scientific (MLSS), ReWalk Robotics (LFWD), Nutriband (NTRB), Inogen (INGN), Elutia (ELUT), YS Biopharma (YS), Carisma Therapeutics (CARM), and Viveon Health Acquisition (VHAQ). These companies are all part of the "medical" sector.
Vicarious Surgical (NYSE:RBOT) and CollPlant Biotechnologies (NASDAQ:CLGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations, dividends and community ranking.
47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 21.7% of CollPlant Biotechnologies shares are held by institutional investors. 11.7% of Vicarious Surgical shares are held by insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Vicarious Surgical has a net margin of 0.00% compared to Vicarious Surgical's net margin of -64.05%. Vicarious Surgical's return on equity of -22.17% beat CollPlant Biotechnologies' return on equity.
CollPlant Biotechnologies has higher revenue and earnings than Vicarious Surgical. CollPlant Biotechnologies is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.
CollPlant Biotechnologies received 125 more outperform votes than Vicarious Surgical when rated by MarketBeat users. Likewise, 58.59% of users gave CollPlant Biotechnologies an outperform vote while only 38.10% of users gave Vicarious Surgical an outperform vote.
Vicarious Surgical presently has a consensus target price of $0.67, indicating a potential upside of 120.53%. CollPlant Biotechnologies has a consensus target price of $11.00, indicating a potential upside of 77.42%. Given CollPlant Biotechnologies' higher probable upside, research analysts plainly believe Vicarious Surgical is more favorable than CollPlant Biotechnologies.
Vicarious Surgical has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 0.23, suggesting that its share price is 77% less volatile than the S&P 500.
In the previous week, Vicarious Surgical and Vicarious Surgical both had 1 articles in the media. Vicarious Surgical's average media sentiment score of 0.59 beat CollPlant Biotechnologies' score of 0.25 indicating that CollPlant Biotechnologies is being referred to more favorably in the news media.
Summary
CollPlant Biotechnologies beats Vicarious Surgical on 9 of the 16 factors compared between the two stocks.
Get CollPlant Biotechnologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CLGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CollPlant Biotechnologies Competitors List
Related Companies and Tools
